No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis

These results suggest that prednisone therapy aimed at improving or preserving FVC in newly- treated pulmonary sarcoidosis can often be reduced in dose, using a treatment regimen that is characterized by early dose tapering.